Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

Nature Medicine

Volumn 12, Issue 10, 2006, Pages 1198-1202

  Trautmann, Lydie ^a,b   Janbazian, Loury ^a,c   Chomont, Nicolas ^a,b   Said, Elias A ^a,b   Gimmig, Sylvain ^a   Bessette, Benoit ^a   Boulassel, Mohamed Rachid ^d   Delwart, Eric ^e   Sepulveda, Homero ^f   Balderas, Robert S ^f   Routy, Jean Pierre ^a,d   Haddad, Elias K ^a,b,c   Sekaly, Rafick Pierre ^a,b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^f BD BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOKINE; PROTEIN DERIVATIVE; PROTEIN PD1; UNCLASSIFIED DRUG;

ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRUS LOAD;

CYTOMEGALOVIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

EID: 33749009709     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1482     Document Type: Article

References (29)

1. Chen, L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4, 336-347 (2004).
2. Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887-3895 (1992).
3. Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765-772 (1996).
4. Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261-268 (2001).
5. Freeman, G.J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
6. Parry, R.V. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543-9553 (2005).
7. Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H. & Riley, J.L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945-954 (2004).
8. Barber, D.L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
9. Zajac, A.J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
10. Wherry, E.J., Barber, D.L., Kaech, S.M., Blattman, J.N. & Ahmed, R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl. Acad. Sci. USA 101, 16004-16009 (2004).
11. Pantaleo, G. & Koup, R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10, 806-810 (2004).
12. Wherry, E.J., Blattman, J.N. & Ahmed, R. Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J. Virol. 79, 8960-8968 (2005).
13. + T cells in chronic human immunodeficiency virus infection. Blood 96, 3094-3101 (2000).
14. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3, 1061-1068 (2002).
15. Zhang, D. et al. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 101, 226-235 (2003).
16. Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605-1613 (1999).
17. Dornadula, G. et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. 282, 1627-1632 (1999).
18. Geels, M.J. et al. Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J. Virol. 77, 12430-12440 (2003).
19. Price, D.A. et al. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 21, 793-803 (2004).
20. Champagne, P. et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106-111 (2001).
21. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8, 379-385 (2002).
22. + T cells. J. Exp. Med. 200, 701-712 (2004).
23. Yang, O.O. et al. Decreased perforin and granzyme B expression in senescent HIV-1-specific cytotoxic T lymphocytes. Virology 332, 16-19 (2005).
24. Lee, K.M. et al. Molecular basis of T cell inactivation by CTLA-4. Science 282, 2263-2266 (1998).
25. + T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J. Virol. 79, 3675-3683 (2005).
26. Wherry, E.J., Blattman, J.N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911-4927 (2003).
27. Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
28. + T cells endowed with proliferative capacity. J. Exp. Med. 198, 1909-1922 (2003).
29. Douek, D.C. et al. A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J. Immunol. 168, 3099-3104 (2002).